Abstract 2256P
Background
In this study, we aimed to investigate the microenvironment of normal mucosa to predict prognosis of stage II/III colorectal cancer (CRC), after surgery.
Methods
We divide the groups using transcriptome sequencing data of prospectively collected tumors and paired normal tissue, obtained from the margins of the resected specimens from 111 patients at Samsung medical center. Groups were defined as follows: tumor-like microenvironment in normal mucosa group (tNME): high tumor signature in normal mucosa; normal microenvironment group (NME): low tumor signature in normal mucosa. The impact of this classification was further evaluated in two independent cohorts (Korean multi-center cohort and TCGA cohort). The microbial, and biological differences between groups were investigated based on 16s rRNA metagenomics and single-cell RNA sequencing.
Results
A total of 38 (34%) were classified as tNME. There were no significant differences in age, sex, TNM stage and CMS between subgroups. With a median follow-up of 57.9 months, tNME showed poorer 3-year recurrence-free survival (RFS) (56.0 % vs. 78.9 %, P=0.008) and 3-year overall survival (OS) (79.0 %vs. 87.7%, P=0.095) compared to NME. These were validated in the Korean multi-center validation cohort (3-year RFS: 55.3% vs. 74.5%, P=0.045), and TCGA cohort (3-year OS: 62.2% vs. 91.7%, P=0.071). Metagenomics exhibited a significantly lower proportion of carcinogenic genus including Fusobacterium, Bacteroides in normal of NME. There were significant differences in beta diversity between tumor and normal in NME, while no significant differences were noted in tNME, which suggests the feature of bacterial biofilm. PathSeq-based computational method of single-cell RNA sequencing revealed more proportion of infected cancer cells in tNME. EMP1 +epithelial cells were correlated with recurrence, and more proportion of this cluster, along with GZMK high CD8 T cells, inflammatory cancer-associated fibroblasts were noted in tumor of tNME, while more proportion of neutrophil was noted in normal of tNME.
Conclusions
The microenvironment of normal mucosa status could be a prognostic biomarker for CRC. The bacterial biofilm with weak intestinal barrier were related to tNME.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bio & Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science & ICT (grant no. NRF2017M3A9A7050803.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2252P - KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Presenter: Marina Milic
Session: Poster session 08
2253P - RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Presenter: Helen Adderley
Session: Poster session 08
2254P - Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Presenter: George Morrissey
Session: Poster session 08
2255P - Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Presenter: Biagio Ricciuti
Session: Poster session 08
2257P - Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Presenter: Antonin Levy
Session: Poster session 08
2258P - Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
Presenter: Lidwien Smabers
Session: Poster session 08
2259P - An artificial neural network system to predict the fraction of type I polarized macrophage
Presenter: Tongji Xie
Session: Poster session 08
2260P - Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Presenter: Andrea Paccone
Session: Poster session 08
2261P - A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Presenter: Nadia Dandachi
Session: Poster session 08
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08